Skip to main content
✦Prime Rate:7.00%✦Fed Funds:3.75%✦5 Yr Treasury:4.78%↓✦10 Yr Treasury:4.98%↓✦30 Yr Treasury:5.32%↓✦30 Yr Mortgage:7.24%·Updated Oct 29, 2026✦Prime Rate:7.00%✦Fed Funds:3.75%✦5 Yr Treasury:4.78%↓✦10 Yr Treasury:4.98%↓✦30 Yr Treasury:5.32%↓✦30 Yr Mortgage:7.24%·Updated Oct 29, 2026
Rates
Complete Mobile Drug Testing

Complete Mobile Drug Testing

The total investment to open a Complete Mobile Drug Testing franchise ranges from $62,000 to $167,249. The initial franchise fee is $40,000. Ongoing royalties are 10%.

What is the Complete Mobile Drug Testing franchise?

Complete Mobile Drug Testing provides mobile drug testing services to employers. The estimated total initial investment is $62,000 to $167,249, and the initial franchise fee is $40,000, according to the 2026 Franchise Disclosure Document.

The royalty is 10 percent of sales. The franchise agreement term is 10 years. The brand was founded in 2011.

According to its Franchise Disclosure Document or public business records, Complete Mobile Drug Testing has 1 location. Cost figures are based on the 2026 Franchise Disclosure Document. To correct a figure, email the current FDD and the differing item numbers to info@peersense.com, and this page will be updated.

2026 FDD ON FILE

Franchising since 2011 · 1 location

Investment

$62,000 to $167,249

Franchise Fee

$40,000

Total Units

1

SBA Lending Activity for Complete Mobile Drug Testing

Loan Activity Score

This franchise has not yet been scored by the Franchise Performance Index. Scores are calculated based on public FDD data, SBA loan performance, and system level metrics.

Key Highlights

Data Insights

Key performance metrics for Complete Mobile Drug Testing based on SBA lending data

Investment Tier

Mid range investment

$62,000 to $167,249 total

Why Complete Mobile Drug Testing Doesn't Appear in Public SBA Data

The SBA 7(a) program publishes loan level data for every approved franchise borrower. Complete Mobile Drug Testing does not currently appear in those public records, and that absence carries useful information for prospective franchisees evaluating this brand.

Likely explanations for the absence

  • With under 25 units system wide, transaction volume is small enough that any SBA activity could fall below the reporting visibility threshold in any given fiscal year.

Absence from SBA records does not mean a brand is un fundable. It typically means the franchise system uses alternative capital sources, or that current franchisees self fund, secure conventional bank financing, or roll over equity from a prior business sale rather than going through an SBA guaranteed 7(a) loan. For prospective Complete Mobile Drug Testing franchisees, the practical question is which financing path actually closes for this brand's profile.

Data window: SBA 7(a) approvals reported through the most recent FOIA release. Absence of Complete Mobile Drug Testing from this window does not reflect lender denial. It reflects no 7(a)-program activity recorded for this brand in the public dataset.

Payment Estimator

Loan Amount$50K
Interest Rate9.5%
Term (Years)10 yr

Estimated Monthly Payment

$642

Principal & Interest only

Indicative only, as of October 1, 2026. Not a quote, commitment or offer of credit. Final pricing, leverage and terms are determined by the lender at underwriting, after full transaction materials are reviewed. PeerSense sources the file. The lender sets pricing. What these terms mean.

Locations

Complete Mobile Drug Testing, unit breakdown

Total Units
N/A
Franchisee Owned
n/a
System Owned
n/a
Closed
n/a

Explore Funding for Complete Mobile Drug Testing

Our business financing consultants help connect you with the right lending partners. Referral fee paid at closing.

Optional: checking the consent box lets us call or text you about your funding. You can still submit without it.

Referral fee at closing

Or get an instant analysis

Scan Your Deal Instantly

3 FDDs Available for Complete Mobile Drug Testing

Review franchise fees, investment ranges, royalties, Item 19 financial data, and year over year trends. Request complimentary access through your PeerSense funding advisor.

Complete Mobile Drug Testing

Page Review

Reviewed by Edward L. Freeman, Founder and Managing Director, PeerSense

  • PeerSense is a capital advisory firm that places commercial financing with direct capital sources; the capital source sets final terms.
  • Edward L. Freeman founded PeerSense in January 2020.
  • He is a Registered Franchise Consultant with Business Alliance, Inc., a credential issued in March 2022, and worked as a franchise consultant there from March 2022 to May 2023.
  • His recorded experience includes a $22 million SBA construction loan, with about $16 million funded on the deal.
  • In the 12 months through September 30, 2026, PeerSense tracked 912 publicly announced financings with a disclosed size of $361.32 billion. PeerSense Capital Data Report · Methodology page

Last reviewed LinkedIn profileAbout Edward Freeman

This is not a franchise offering and does not constitute financial, investment, or legal advice. Data is sourced from Franchise Disclosure Documents (FDDs), public filings, and third party sources and may contain inaccuracies. The figures reflect the FDD on file for the year shown and may have been superseded or extracted with errors. PeerSense is not a financial advisor, attorney, or accountant. Always consult the brand's current FDD and seek professional guidance from a qualified attorney, accountant, or financial advisor before making any franchise investment decision. See full Terms & Conditions.